Our company is named after Hebe, the Greek Goddess of Youth. While we do not possess Hebe’s mythological power of restoring youthfulness, we have developed breakthrough technologies focused on fighting disease and restoring health at the cellular level.
Our mission is to develop and commercialize cell-based therapeutics to treat incurable diseases and contribute to the fields of regenerative medicine and immuno-oncology.
- Groundbreaking, patented technology with proven results
- Leading biologists and researchers
- Collaborative, clinical approach
- Infinitely reproducible natural killer (NK) cells
- Retinal photoreceptor progenitors (RPRPs)
What we Do
Patented scalable natural killer (NK) cell technology is the heart of our work here at HebeCell. The process of producing NK cells indefinitely is simple, but the results and possibilities are limitless. We have been researching and developing this technology since 2016, and we are working hard to get it ready for clinical trials.
NK Functional Assay
The iPS-NK Bioreactor
Scalable and versatile natural killer cell bioreactors.
No other company or research lab in the world can produce cancer-specific natural killer (NK) cells as safely or as efficiently as HebeCell. That is because we have created a way to produce an indefinite supply of NK cells without the help of other abnormal cells or additives that can be harmful to patients. Our NK cells develop while suspended in a liquid solution within a bioreactor, allowing them to reproduce indefinitely. With this patented, scalable system, the possibilities are limitless.
Unlike CAR-T cells, HebeCell’s CAR-NK cells are allogeneic — that is, they are not specific to a single patient, so once they have been produced, any patient can use them. This creates the opportunity for off-the-shelf cancer treatments that can be stocked in the oncology department of any hospital.